In a nutshell This study examined if anti-androgen therapy for prostate cancer is associated with depression. This study concluded that the risk of depression is increased in these patients. Some background Anti-androgen therapy or androgen deprivation therapy (ADT) is commonly used in the treatment of prostate cancer. Androgens (such as...
Read MoreTreatment(s) now being considered-Hormonal therapy Posts on Medivizor
Evaluating optimal duration of androgen deprivation therapy in high risk prostate cancer
In a nutshell This study aimed to investigate the effect of the length of androgen deprivation therapy (ADT) when used with radiotherapy in patients with prostate cancer. This study found that 18 months ADT led to similar overall survival and better quality of life as compared to 36 months in these patients. Some background...
Read MoreComparing two hormone therapy drugs in men with advanced, non-metastatic prostate cancer
In a nutshell This study aimed to compare two hormone therapies, gonadotropin-releasing hormone (GnRH) agonists and anti-androgen therapy (AA) in men with advanced, non-metastatic prostate cancer. This study found that the two therapies have similar outcomes, but by starting with AA treatment may reduce side effects associated with GnRH...
Read More10 years of treatment vs 5 years of treatment with hormone therapy in patients with early stage breast cancer.
In a nutshell This study wanted to find out if continuing hormone therapy for 10 years was more effective than doing it for 5 years in patients with early stage breast cancer. The study found that the patients who continued treatment for 10 years survived for longer without the disease coming back compared to those who were only treated for 5...
Read MoreLooking for patients with prostate cancer who have had a rise in PSA after prostate removal surgery
In a nutshell This trial is examining the effectiveness of different hormone therapy regimes for patients whose prostate specific antigen (PSA; a protein elevated in prostate cancer) levels rise after prostate removing surgery. The main outcome to be measured will be the change in PSA levels. The details The best standard treatment...
Read MoreShould men with castration-resistant metastatic prostate cancer receive further hormone therapy?
In a nutshell This study aimed to discover the optimal timing of hormone therapies in combination with androgen-deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer. This study found that treatment with a second hormone therapy after prostate cancer becomes immune to hormone treatment is associated...
Read MoreBreast cancer treatment with Tamoxifen and its relation to Fatty Liver Disease
In a nutshell This study looked at the risk factors and protective factors surrounding non-alcoholic fatty liver disease in relation to tamoxifen (Novaldex) therapy for women with breast cancer. The authors found that a high BMI was a risk factor for tamoxifen related fatty liver disease, while exercise was a protective factor. Some background...
Read MoreEncouraging men with prostate cancer to monitor bone health
In a nutshell This study aimed to compare different strategies of promoting bone health. This study found that educational strategies to improve bone health care are feasible and are associated with improved bone mineral density ordering in men receiving androgen deprivation therapy. Some background Bone health is important for men receiving...
Read MoreThe use of biomarkers in advanced prostate cancer with bone tumors
In a nutshell The aim of this study was to determine the effect of biomarkers to tailor therapy in advanced prostate cancer in patients receiving abiraterone (Zytiga) treatment. The authors concluded that alkaline phosphatase (ALP- protein elevated in the blood), lactate dehydrogenase (LDH – protein involved in tumor growth) and prostate...
Read MoreThe effect of apalutamide on advanced, hormone-resistant prostate cancer
In a nutshell The authors aimed to determine the effectiveness of apalutamide before or after treatment with abiraterone acetate (Zytiga) and prednisone (Deltasone) in men with advanced, hormone-resistant prostate cancer. The authors concluded that apalutamide was a safe treatment option and demonstrated effectiveness against advanced,...
Read MoreWhat are the side effects of non-hormonal drugs for hot flashes?
In a nutshell This study aimed to investigate the frequency and severity of the adverse events associated with non-hormonal drugs (NHD) used to treat hot flashes in breast cancer survivor patients. This study concluded that the use of high-dose NHD led to increased rates of adverse events when compared to patients not using NHD. Some...
Read MoreCan PSA surge impact hormone-resistant prostate cancer in the long-term?
In a nutshell The authors aimed to determine the impact of prostate specific antigen (PSA) surge in hormone-resistant prostate cancer patients following abiraterone acetate (Zytiga) treatment. The authors concluded that PSA surge occurred in both chemotherapy-treated and chemotherapy-naïve patients treated with abiraterone acetate with no...
Read More
